Azurrx Biopharma, Inc. (AZRX) SEC Filing 8-K Material Event for the period ending Wednesday, April 29, 2020

Azurrx Biopharma, Inc.

CIK: 1604191 Ticker: AZRX

View differences made from one to another to evaluate Azurrx Biopharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Azurrx Biopharma, Inc..


Assess how Azurrx Biopharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Azurrx Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: AZRX
CIK: 1604191
Form Type: 8-K Corporate News
Accession Number: 0001415889-20-001099
Submitted to the SEC: Fri May 01 2020 4:43:41 PM EST
Accepted by the SEC: Fri May 01 2020
Period: Wednesday, April 29, 2020
Industry: Pharmaceutical Preparations
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: